KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBIT Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBIT Margin readings, the most recent being 36777.54% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 3678097.0% to 36777.54% in Q4 2025 year-over-year; TTM through Dec 2025 was 72.71%, a 7327.0% increase, with the full-year FY2025 number at 38.98%, up 3954.0% from a year prior.
  • EBIT Margin hit 36777.54% in Q4 2025 for Biocryst Pharmaceuticals, up from 18.56% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 36777.54% in Q4 2025 to a low of 269.57% in Q1 2021.
  • Median EBIT Margin over the past 5 years was 24.05% (2022), compared with a mean of 1795.81%.
  • Biggest five-year swings in EBIT Margin: soared 623bps in 2022 and later surged 3678097bps in 2025.
  • Biocryst Pharmaceuticals' EBIT Margin stood at 110.64% in 2021, then skyrocketed by 47bps to 58.22% in 2022, then increased by 22bps to 45.68% in 2023, then surged by 92bps to 3.43% in 2024, then soared by 1073192bps to 36777.54% in 2025.
  • The last three reported values for EBIT Margin were 36777.54% (Q4 2025), 18.56% (Q3 2025), and 18.23% (Q2 2025) per Business Quant data.